Business Context and Reporting Period
This Form 8-K is a current report filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on January 9, 2018, covering events that occurred on January 8, 2018. The filing addresses Item 5.02 regarding the departure of certain officers and the appointment of new officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a corporate governance report rather than a financial statement.
Material Changes
- Executive Title Change: Troy Rhonemus's title was changed from Chief Operating Officer (COO) to Executive Vice President, effective immediately. He retains substantially the same operational responsibilities.
- New Appointment: Robert Fried was appointed as Chief Operating Officer, effective immediately. He continues to serve as President, Chief Strategy Officer, and a member of the Board of Directors.
- Compensation Context: The filing references a prior acquisition of Healthspan Research, LLC, where Mr. Fried received 339,595 shares of common stock and a $32,500 payment. An additional payment of $100,000 is scheduled for Mr. Fried on March 12, 2018.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. It notes that there are no undisclosed arrangements or family relationships influencing Mr. Fried's selection as COO.
Investor Verification Checklist
- Verify the distinction between the registrant (ChromaDex Corporation) and the company name provided in the request metadata (Niagen Bioscience, Inc.).
- Confirm the effective date of Robert Fried's new role as COO (January 8, 2018).
- Review the terms of the Executive Employment Agreement dated March 12, 2017, as amended, regarding Mr. Fried's compensation.
- Monitor the scheduled $100,000 payment to Mr. Fried due on March 12, 2018.